CYP26A1 and breast carcinoma: In noncompetitive RT–PCR, we detected weak RARβ2 and CYP26A1 (Figure 2A) expression in the RA-resistant breast cancer cell line, MDA-MB-231, after treatment with aza-CdR and aRA, in a dose-dependent manner.